SIMBRINZA: payments to doctors
Payments that named SIMBRINZA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $931K
- Providers
- 5,435
- Transactions
- 12,756
- Average per transaction
- $73
The per-transaction average — $73 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,435 providers the average total is $171, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Alcon | $924,498 | 99.3% |
| Alcon Research LLC | $3,920 | 0.4% |
| Novartis | $2,533 | 0.3% |